SI2400954T1 - Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli - Google Patents
Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soliInfo
- Publication number
- SI2400954T1 SI2400954T1 SI201031356A SI201031356A SI2400954T1 SI 2400954 T1 SI2400954 T1 SI 2400954T1 SI 201031356 A SI201031356 A SI 201031356A SI 201031356 A SI201031356 A SI 201031356A SI 2400954 T1 SI2400954 T1 SI 2400954T1
- Authority
- SI
- Slovenia
- Prior art keywords
- solifenacin
- pharmaceutically acceptable
- acceptable salts
- dosage forms
- oral dosage
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 title 1
- 229960003855 solifenacin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200900056 | 2009-02-27 | ||
| SI200900159 | 2009-06-08 | ||
| PCT/EP2010/001262 WO2010097243A2 (en) | 2009-02-27 | 2010-03-01 | Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts |
| EP10705984.2A EP2400954B2 (en) | 2009-02-27 | 2010-03-01 | Process for forming solid oral dosage forms of solifenacin succinate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2400954T1 true SI2400954T1 (sl) | 2017-02-28 |
Family
ID=42041747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201031356A SI2400954T1 (sl) | 2009-02-27 | 2010-03-01 | Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2400954B2 (sl) |
| DK (1) | DK2400954T3 (sl) |
| EA (1) | EA023529B1 (sl) |
| ES (1) | ES2609061T3 (sl) |
| HR (1) | HRP20161730T1 (sl) |
| HU (1) | HUE030376T2 (sl) |
| PL (1) | PL2400954T3 (sl) |
| SI (1) | SI2400954T1 (sl) |
| WO (1) | WO2010097243A2 (sl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201291189A1 (ru) * | 2010-05-07 | 2013-05-30 | Зентива К.С. | Фармацевтическая композиция, содержащая солифенацин, и способ его получения |
| EP2500013B1 (en) | 2011-03-15 | 2019-10-02 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical composition comprising solifenacin |
| EP2778167A1 (en) | 2013-03-11 | 2014-09-17 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt |
| KR20150092385A (ko) * | 2014-02-03 | 2015-08-13 | 씨제이헬스케어 주식회사 | 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법 |
| CN104940152B (zh) * | 2014-03-31 | 2017-12-29 | 成都国为生物医药有限公司 | 一种含有琥珀酸索利那新的药物组合物 |
| CN105012961B (zh) * | 2014-04-17 | 2020-07-21 | 燃点(南京)生物医药科技有限公司 | 稳定的药物组合物及其制备方法 |
| WO2015170237A1 (en) * | 2014-05-05 | 2015-11-12 | Torrent Pharmaceuticals Limited | Stable solifenacin composition |
| CN105362245A (zh) * | 2014-08-30 | 2016-03-02 | 山东中泰药业有限公司 | 含有索利那新的片剂组合物及其制备方法 |
| CN104523628B (zh) * | 2014-12-24 | 2017-08-25 | 乐普药业股份有限公司 | 一种可粉末直接压片的琥珀酸索利那新片剂及其制备方法 |
| US20180214453A1 (en) * | 2015-08-05 | 2018-08-02 | Interquim, S.A. | Rivaroxaban pharmaceutical compositions |
| CN105395494A (zh) * | 2015-11-27 | 2016-03-16 | 浙江华义医药有限公司 | 一种含琥珀酸索利那新的药物组合物及其制备方法 |
| WO2019031560A1 (ja) | 2017-08-08 | 2019-02-14 | 日本合成化学工業株式会社 | 医薬錠剤、およびその製造方法 |
| KR101977890B1 (ko) * | 2018-05-08 | 2019-05-13 | 씨제이헬스케어 주식회사 | 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU508480B2 (en) | 1977-04-13 | 1980-03-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Microcrystalline cellulose excipient and pharmaceutical composition containing thesame |
| EP0876814A1 (en) | 1997-05-07 | 1998-11-11 | "PHARLYSE", Société Anonyme | Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it |
| AU2005226357B2 (en) * | 2004-03-25 | 2010-07-01 | Astellas Pharma Inc. | Composition for solid pharmaceutical preparation of solifenacin or salt thereof |
| RU2008120332A (ru) | 2005-12-20 | 2010-01-27 | Пфайзер Продактс Инк. (Us) | Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист |
| WO2008013851A2 (en) * | 2006-07-24 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Processes for preparing polymorphic forms of solifenacin succinate |
| EP2146693A2 (en) * | 2007-04-11 | 2010-01-27 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
| EP2018850A1 (en) | 2007-07-24 | 2009-01-28 | Ratiopharm GmbH | Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof |
| SI3067353T1 (sl) * | 2008-07-29 | 2018-03-30 | Krka, D.D., Novo Mesto | Proces za pripravo solifenacinijevih soli in njihovo vključitev v farmacevtske dozirne oblike |
-
2010
- 2010-03-01 EP EP10705984.2A patent/EP2400954B2/en active Active
- 2010-03-01 HU HUE10705984A patent/HUE030376T2/en unknown
- 2010-03-01 PL PL10705984T patent/PL2400954T3/pl unknown
- 2010-03-01 SI SI201031356A patent/SI2400954T1/sl unknown
- 2010-03-01 DK DK10705984.2T patent/DK2400954T3/en active
- 2010-03-01 ES ES10705984.2T patent/ES2609061T3/es active Active
- 2010-03-01 WO PCT/EP2010/001262 patent/WO2010097243A2/en not_active Ceased
- 2010-03-01 EA EA201190161A patent/EA023529B1/ru not_active IP Right Cessation
- 2010-03-01 HR HRP20161730TT patent/HRP20161730T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201190161A1 (ru) | 2012-02-28 |
| WO2010097243A3 (en) | 2011-06-16 |
| ES2609061T3 (es) | 2017-04-18 |
| PL2400954T3 (pl) | 2017-04-28 |
| EP2400954B1 (en) | 2016-09-28 |
| WO2010097243A2 (en) | 2010-09-02 |
| DK2400954T3 (en) | 2017-01-16 |
| EP2400954B2 (en) | 2024-06-26 |
| EA023529B1 (ru) | 2016-06-30 |
| HRP20161730T1 (hr) | 2017-02-24 |
| EP2400954A2 (en) | 2012-01-04 |
| HUE030376T2 (en) | 2017-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2400954T1 (sl) | Postopek za pripravo trdne oralne dozirne oblike solifenacina in njegovih farmacevtsko sprejemljivih soli | |
| ZA200906899B (en) | Process for preparation of erlotinib and its pharmaceutically acceptable salts | |
| IL206500A0 (en) | Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
| EP2499147A4 (en) | IMPROVED METHODS FOR THE PRODUCTION OF PRASUGREL AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF | |
| PL2588090T3 (pl) | Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole | |
| PL3363797T3 (pl) | Doustna postać dawkowania inhibitorów kinazy regulującej sygnał apoptozy | |
| IL238477A (en) | Pharmaceutical dosage form for oral administration of the bcl-2 family inhibitor | |
| IL217755A (en) | A process for preparing parametric active compounds | |
| IL231485A (en) | Oral dosage forms of medicinal preparations are resistant to abuse | |
| PL3067353T3 (pl) | Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania | |
| SI2241553T1 (sl) | Postopek za sintezo ivabradina in njegovih farmacevtsko sprejemljivih kislih dodatnih soli | |
| IL223311A0 (en) | Oral dosage forms of bendamustine | |
| SI2736909T1 (sl) | Proces za pripravo sitagliptina in njegovih farmacevtsko sprejemljivih soli | |
| EP2435052A4 (en) | SOLID PHARMACEUTICAL FORMS OF LAMIVUDIN ORAL ADMINISTRATION | |
| SI2536396T1 (sl) | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan | |
| PL2291374T3 (pl) | Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej | |
| PL2241554T3 (pl) | Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem dopuszczalnym farmaceutycznie | |
| HU1000299D0 (en) | Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation | |
| EP2121729A4 (en) | PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF | |
| SI2585051T1 (sl) | Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli | |
| SI2451809T1 (sl) | Postopek za pripravo in čiščenje soli solifenacina | |
| EP2389360A4 (en) | METHOD FOR PRODUCING ZOFENOPRIL AND PHARMACEUTICAL ACCEPTIC SALTS THEREFOR | |
| ZA201000159B (en) | Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof | |
| SI2607354T1 (sl) | Nov postopek sinteze ivabradina in njegovih dodatnih soli s farmacevtsko sprejemljivo kislino | |
| SI2595979T1 (sl) | Proces za čiščenje farmacevtsko sprejemljivih soli Escitaloprama |